446 related articles for article (PubMed ID: 12596016)
1. [Facioscapulohumeral muscular dystrophy. The spectrum of clinical manifestations and molecular genetic changes].
Krasnianski M; Neudecker S; Eger K; Schulte-Mattler W; Zierz S
Nervenarzt; 2003 Feb; 74(2):151-8. PubMed ID: 12596016
[TBL] [Abstract][Full Text] [Related]
2. Typical facioscapulohumeral dystrophy phenotype in patients without FSHD 4q35 deletion.
Krasnianski M; Neudecker S; Eger K; Jakubiczka S; Zierz S
J Neurol; 2003 Sep; 250(9):1084-7. PubMed ID: 14504970
[TBL] [Abstract][Full Text] [Related]
3. Atypical phenotypes in patients with facioscapulohumeral muscular dystrophy 4q35 deletion.
Krasnianski M; Eger K; Neudecker S; Jakubiczka S; Zierz S
Arch Neurol; 2003 Oct; 60(10):1421-5. PubMed ID: 14568813
[TBL] [Abstract][Full Text] [Related]
4. FSHD-like patients without 4q35 deletion.
Yamanaka G; Goto K; Ishihara T; Oya Y; Miyajima T; Hoshika A; Nishino I; Hayashi YK
J Neurol Sci; 2004 Apr; 219(1-2):89-93. PubMed ID: 15050443
[TBL] [Abstract][Full Text] [Related]
5. Expression profile of FSHD supports a link between retinal vasculopathy and muscular dystrophy.
Osborne RJ; Welle S; Venance SL; Thornton CA; Tawil R
Neurology; 2007 Feb; 68(8):569-77. PubMed ID: 17151338
[TBL] [Abstract][Full Text] [Related]
6. Facioscapulohumeral muscular dystrophy. Phenotype-genotype correlation in patients with borderline D4Z4 repeat numbers.
Butz M; Koch MC; Müller-Felber W; Lemmers RJ; van der Maarel SM; Schreiber H
J Neurol; 2003 Aug; 250(8):932-7. PubMed ID: 12928911
[TBL] [Abstract][Full Text] [Related]
7. Genotype-phenotype study in an FSHD family with a proximal deletion encompassing p13E-11 and D4Z4.
Deak KL; Lemmers RJ; Stajich JM; Klooster R; Tawil R; Frants RR; Speer MC; van der Maarel SM; Gilbert JR
Neurology; 2007 Feb; 68(8):578-82. PubMed ID: 17229919
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnosis of facioscapulohumeral muscular dystrophy.
Upadhyaya M; Cooper DN
Expert Rev Mol Diagn; 2002 Mar; 2(2):160-71. PubMed ID: 11962336
[TBL] [Abstract][Full Text] [Related]
9. [Translocation between chromosomes 4q35 and 10q26 in facioscapulohumeral muscular dystrophy].
Su QX; Zhang C; Zeng Y; Lu XL; Liu XR; Wang ZH; Zhu YZ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Oct; 25(5):581-4. PubMed ID: 14650163
[TBL] [Abstract][Full Text] [Related]
10. Clinical and histopathological heterogeneity in patients with 4q35 facioscapulohumeral muscular dystrophy (FSHD).
Wood-Allum C; Brennan P; Hewitt M; Lowe J; Tyfield L; Wills A
Neuropathol Appl Neurobiol; 2004 Apr; 30(2):188-91. PubMed ID: 15043716
[No Abstract] [Full Text] [Related]
11. [Progress in researches on the molecular genetics of facioscapulohumeral muscular dystrophy].
Su Q; Zhang C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2001 Oct; 18(5):398-401. PubMed ID: 11592052
[TBL] [Abstract][Full Text] [Related]
12. [Facioscapuloperoneal muscular dystrophy: correlation between a phenotype and genotype].
Rudenko DI; Kazakov BM; Skoromets AA; Magomedova NK
Patol Fiziol Eksp Ter; 2009; (2):22-7. PubMed ID: 19537084
[TBL] [Abstract][Full Text] [Related]
13. [Gene diagnosis of facioscapulohumeral muscular dystrophy].
Zhang JL; Shen DG; Zhou PK; Liu JW; Jia N; Liu H; Wang HB; Yang SX; Frants RR
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Jun; 20(3):232-4. PubMed ID: 12778451
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic elevation of serum creatine kinase leading to the diagnosis of 4q35 facioscapulohumeral muscular dystrophy.
Zouvelou V; Manta P; Kalfakis N; Evdokimidis I; Vassilopoulos D
J Clin Neurosci; 2009 Sep; 16(9):1218-9. PubMed ID: 19502063
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic challenges in facioscapulohumeral muscular dystrophy.
Sacconi S; Salviati L; Bourget I; Figarella D; Péréon Y; Lemmers R; van der Maarel S; Desnuelle C
Neurology; 2006 Oct; 67(8):1464-6. PubMed ID: 17060574
[TBL] [Abstract][Full Text] [Related]
16. [Facioscapulohumeral muscular dystrophy (FSHD)].
Funakoshi M; Goto K; Kim BY; Arahata K
Nihon Rinsho; 1997 Dec; 55(12):3181-5. PubMed ID: 9436432
[TBL] [Abstract][Full Text] [Related]
17. Testing the position-effect variegation hypothesis for facioscapulohumeral muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 4q.
Jiang G; Yang F; van Overveld PG; Vedanarayanan V; van der Maarel S; Ehrlich M
Hum Mol Genet; 2003 Nov; 12(22):2909-21. PubMed ID: 14506132
[TBL] [Abstract][Full Text] [Related]
18. Rimmed vacuoles in facioscapulohumeral muscular dystrophy: a unique ultrastructural feature.
Neudecker S; Krasnianski M; Bahn E; Zierz S
Acta Neuropathol; 2004 Sep; 108(3):257-9. PubMed ID: 15221332
[TBL] [Abstract][Full Text] [Related]
19. [Application of the Bgl II-Bln I dosage test to gene diagnosis of facioscapulohumeral muscular dystrophy 1A gene].
Su QX; Zhang C; Xie YM; Zeng Y; Liu XR; Lu XL; Zhu YZ
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Jun; 21(3):245-7. PubMed ID: 15192827
[TBL] [Abstract][Full Text] [Related]
20. Severe phenotype in infantile facioscapulohumeral muscular dystrophy.
Klinge L; Eagle M; Haggerty ID; Roberts CE; Straub V; Bushby KM
Neuromuscul Disord; 2006 Oct; 16(9-10):553-8. PubMed ID: 16934468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
